EHA 2024 – Consuelo Bertossi
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationConsuelo Bertossi explains how TP53 mutations affect the prognosis of CLL patients and their impact on treatment decisions. She also discusses the significance of co-occurring genetic alterations and highlights the influence of TP53 mutations on the efficacy of different treatment approaches in CLL, ahead of her presentation at this year’s EHA congress.
Here is the full EHA 2024 report.
More posts
Preface – EHA 2024
At the European Hematology Association (EHA) congress held in Madrid, Spain, and virtually from 13th–16th June 2024, world-leading experts from 150 countries presented cutting-edge research and clinical trials. This year, we witnessed significant advancements in the treatment of chronic lymphocytic leukemia (CLL).